ADVERTISEMENT
CAPOX With Intermittent Oxaliplatin Promising Treatment for Colon Cancer
San Francisco—Findings from a phase 2 clinical trial presented at the 2020 ASCO Gastrointestinal Cancers Symposium suggest that combining CAPOX with intermittent oxaliplatin could be equally as effective as adjuvant chemotherapy after curative resection in patients with stage II/III colon cancer.
“The aim of this study was to evaluate the efficacy and safety of CAPOX with intermittent use of oxaliplatin compared to continuous use of oxaliplatin as an adjuvant setting for colon cancer,” explained Masanori Nakamura, MD, Department of Surgery, Konan Kosei Hospital, Konan, Japan, and colleagues.
A total of 200 patients were randomized to receive CAPOX with continuous oxaliplatin for 8 cycles or CAPOX with intermittent oxaliplatin. The intermittent treatment regimen included 2 cycles of CAPOX, 4 cycles of capecitabine without oxaliplatin, and then another 2 cycles of CAPOX.
The primary end points were disease-fee survival (DFS) 3 years after surgery and rate of peripheral sensory neuropathy (PSN) 1 year after surgery.
After a median follow-up period of 39 months, the 3-year DFS was 78% in the continuous arm and 82% in the intermittent arm (hazard ratio, 0.80; 95% CI, 0.42-1.52; P= .49).
At 1 year after surgery, the frequencies of PSN were 58% and 80% in the continuous and intermittent arms, respectively.
Dr Nakamuraet al noted that among patients with stage III disease, the 3-year DFS rate was 76% in recipients of continuous treatment versus 80% in recipients of intermittent therapy.
“CAPOX with planned intermittent use of oxaliplatin could be equally effective as an adjuvant setting for colon cancer, and substantially reduce long-term PSN and potential improve patient quality of life,” they concluded.—Kaitlyn Manasterski
Nakamura M, Nakayama G, Ishigure K, et al. Randomized phase II trial of CAPOX with continuous versus intermittent use of oxaliplatin as an adjuvant chemotherapy after curative resection of stage II/III colon cancer (CCOG-1302 study). Presented at: the 2020 Gastrointestinal Cancers Symposium; January 23-25, 2020; San Francisco, CA. Abstract 95.
